1 – 4 of 4
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=""
width=""
height=""
allowtransparency="true"
frameborder="0">
</iframe>
- 2025
-
Mark
Health-Related Quality of Life, Physical Activity and Joint Health in People With Severe Haemophilia A Receiving Emicizumab : Results From the Phase IV HemiNorth 2 Study
(2025) In Haemophilia
- Contribution to journal › Article
- 2023
-
Mark
Matching-adjusted indirect comparison of bleeding outcomes in severe haemophilia A : Comparing valoctocogene roxaparvovec gene therapy, emicizumab prophylaxis, and FVIII replacement prophylaxis
- Contribution to journal › Article
-
Mark
Dilemmas on emicizumab in children with haemophilia A : A survey of strategies from PedNet centres
- Contribution to journal › Article
- 2022
-
Mark
Immune tolerance induction in the era of emicizumab – still the first choice for patients with haemophilia A and inhibitors?
- Contribution to journal › Article